Top Markets
Coin of the day
Pharnext S.A. Pharnext S.A.

Pharnext S.A.

ALPHA
株式のランク #42432
Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm... Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm dedicated to creating treatments for a range of neurodegenerative disorders, encompassing both rare (orphan) and common forms. Its pipeline features SYNGILITY, which has advanced through Phase III trials for Charcot-Marie-Tooth disease type 1A (CMT1A). Additionally, PXT864 has concluded Phase II clinical studies for Alzheimer's disease, and is also being explored for its potential in Parkinson's disease and amyotrophic lateral sclerosis (ALS). Pharnext also innovates with PLEOTHERAPY, a proprietary platform that harnesses big genetic data and artificial intelligence. In a collaborative effort, the company holds an agreement with the University Hospital Institute Mediterranee Infection to assess existing pharmaceuticals for their potential application against the COVID-19 virus. The organization was established in 2007, with its main offices located in Issy-Les-Moulineaux, France.
株価
$0.00023723
最終同期: 2024-08-26
時価総額
$1.41K
変化(1日)
111.67%
変化(1年)
0.00%
FR
取引 Pharnext S.A. (ALPHA)

カテゴリー

Pharnext S.A.(ALPHA)のEPS
December 2023 時点のEPS TTM: $-77.35M
Pharnext S.A.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は$-77.35Mです。2022年末には、EPSは$-11.16Kで、2021年のEPS$-11.45Kと減少でした。
Pharnext S.A.のEPS履歴(2013から2026まで)
各年末時点のEPS
EPS 変化
2026 (TTM) $-77.35M 35,598,509.46%
2023 $-217.28 -98.05%
2022 $-11.16K -2.49%
2021 $-11.45K 69.15%
2020 $-6.77K -21.06%
2019 $-8.57K -15.43%
2018 $-10.14K -100.00%
2017 $-6.00Qa 14.04%
2016 $-5.26Qa 44,068,612,420.18%
2015 $-11.94M -8.06%
2014 $-12.98M 1.29%
2013 $-12.82M 0.00%
同様の企業または競合他社のEPS
企業 EPS EPSの差
$17.32 -100.00%
US
$27.74 -100.00%
NL
- -
CH
$13.70 -100.00%
BE
- -
KR